Recombinant Pig ATP synthase subunit a (MT-ATP6)

What is MT-ATP6 and what is its role in mitochondrial function?

MT-ATP6 (Mitochondrially Encoded ATP Synthase Membrane Subunit 6) is a protein-coding gene that encodes a key component of mitochondrial ATP synthase (Complex V) . It contributes to the proton-transporting activity of ATP synthase through a rotational mechanism and is involved in mitochondrial ATP synthesis coupled with proton transport . The protein functions as part of the F0 domain, forming a critical component of the proton channel within the mitochondrial membrane .

The ATP6 protein is essential for the synthesis of ATP, which serves as life's "universal energy currency" and is responsible for fueling nearly all cellular processes, from nerve impulse propagation to DNA synthesis . MT-ATP6 may play a direct role in the translocation of protons across the membrane, which is crucial for the chemiosmotic mechanism of ATP production .

How does ATP synthase structure relate to its function?

ATP synthase consists of two major structural domains:

• F1 domain: Contains the extramembraneous catalytic core

• F0 domain: Contains the membrane proton channel

These domains are linked together by a central stalk and a peripheral stalk . During catalysis, ATP synthesis in the catalytic domain of F1 is coupled via a rotary mechanism of the central stalk subunits to proton translocation .

The MT-ATP6 gene encodes subunit a of ATP synthase, which forms part of the proton channel along with the c-ring . This channel facilitates the flow of protons across the mitochondrial membrane, which drives the rotational motion that powers ATP synthesis . The functional integration of these components allows for the efficient conversion of the proton gradient energy into chemical energy stored in ATP.

What diseases are associated with MT-ATP6 mutations?

MT-ATP6 mutations are associated with several mitochondrial disorders:

Recent research has expanded the clinical and molecular spectrum of MT-ATP6-related disorders to include these additional phenotypes . MT-ATP6 has also been implicated in Leber hereditary optic neuropathy, Parkinson's disease, multiple sclerosis, and systemic lupus erythematosus, though these associations require further investigation .

What are the optimal storage conditions for recombinant pig ATP synthase proteins?

For recombinant pig ATP synthase proteins, the following storage conditions are recommended:

• Long-term storage: -20°C to -80°C (with -80°C preferred for extended storage)

• Working aliquots: 4°C for up to one week

• Avoid repeated freeze-thaw cycles as they can compromise protein integrity

For reconstitution:

• Briefly centrifuge the vial prior to opening to bring contents to the bottom

• Reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C

• The default final concentration of glycerol is typically 50%

These conditions help maintain protein stability and functionality for accurate experimental results.

What methods are used to assess MT-ATP6 mutations' impact on ATP synthase function?

Several methodological approaches can be employed to assess the functional consequences of MT-ATP6 mutations:

• Blue-native gel electrophoresis (BN-PAGE): Used to evaluate complex V assembly. Multiple bands observed in cultured fibroblasts and skeletal muscle tissue suggest impaired complex V assembly in patients with MT-ATP6 mutations .

• Microscale oxygraphy: Measures oxygen consumption rates to assess:

  • Basal respiration (typically reduced with pathogenic mutations)

  • ATP synthesis capacity (often diminished)

  • Reactive oxygen species (ROS) generation (frequently increased)

• Transmitochondrial cybrid cell studies: Useful for confirming pathogenicity of novel variants by transferring mitochondria from patient cells to rho-zero cells lacking mtDNA. This approach was used to confirm the deleterious effects of the m.8782 G>A; p.(Gly86*) mutation .

• Yeast models: S. cerevisiae has been successfully used as a model organism to study the effects of variants in MT-ATP6 gene. This approach has helped understand how amino acid substitutions impact proton translocation through the channel formed by subunit a and the c-ring of ATP synthase at the molecular level .

How does heteroplasmy affect the expression and severity of MT-ATP6 mutations?

Heteroplasmy (the presence of both wild-type and mutant mtDNA in varying proportions) significantly impacts the expression and severity of MT-ATP6 mutations. Research has demonstrated that truncating MT-ATP6 mutations exhibit highly variable mutant levels across different tissue types .

Key considerations regarding heteroplasmy in MT-ATP6 research:

• Tissue-specific variation: The proportion of mutant mtDNA can vary widely between different tissues in the same patient, contributing to the diverse clinical manifestations observed in MT-ATP6-related disorders .

• Threshold effect: Clinical symptoms typically manifest when the proportion of mutated mtDNA exceeds a tissue-specific threshold. This threshold varies by tissue type, with highly aerobic tissues like brain, heart, and muscle typically having lower thresholds for dysfunction .

• Genetic counseling implications: The variable distribution of mutant mtDNA across tissues is an important consideration during genetic counseling for patients with MT-ATP6 mutations. This variability contributes to the challenges in predicting disease progression and transmission risk .

• Diagnostic approach: Multiple tissue sampling may be necessary for accurate molecular diagnosis of MT-ATP6-related disorders, as mutation load may be below detection threshold in some tissues while causing dysfunction in others .

What are the most effective model systems for studying MT-ATP6 function and pathology?

Several model systems have proven valuable for investigating MT-ATP6 function and disease mechanisms:

Research has demonstrated that yeast S. cerevisiae can be particularly effective for studying the effects of variants in MT-ATP6, providing insights into how substitutions impact proton translocation through the channel formed by subunit a and the c-ring of ATP synthase at the molecular level .

How do mutations in MT-ATP6 affect ATP synthesis and mitochondrial function?

Mutations in MT-ATP6, particularly truncating mutations, can have profound effects on ATP synthesis and broader mitochondrial function:

The severity of these effects often correlates with the mutation load (degree of heteroplasmy) and the specific nature of the mutation. Truncating mutations typically have more severe functional consequences than missense mutations .

What antibody selection criteria are important for MT-ATP6 research?

When selecting antibodies for MT-ATP6 research, consider the following criteria:

• Specificity and reactivity: Choose antibodies with validated reactivity to the species under investigation. For example, antibody 68442-1-Ig has demonstrated reactivity with human and rat samples .

• Application compatibility: Ensure the antibody is validated for your intended applications. For instance, the 68442-1-Ig antibody is recommended for Western Blot with dilutions of 1:5000-1:50000 .

• Target epitope consideration:

  • For recombinant proteins, antibodies targeting conserved regions may provide better cross-species reactivity

  • Consider whether the antibody recognizes the native conformation or denatured forms of the protein

• Validation data: Review the antibody's validation data, including:

  • Observed molecular weight (for ATP6, typically 25-30 kDa)

  • Positive detection in relevant tissues (e.g., heart tissue, liver tissue, cerebellum)

  • Published applications

• Storage and handling: Follow manufacturer recommendations for optimal antibody performance:

  • Typical storage at -20°C in PBS with 0.02% sodium azide and 50% glycerol pH 7.3

  • Aliquoting may be unnecessary for -20°C storage

  • Stability generally maintained for one year after shipment

• Titration optimization: It is recommended to titrate antibodies in each specific testing system to obtain optimal results, as optimal dilutions may be sample-dependent .

How do MT-ATP6 mutations influence mitochondrial membrane interactions?

The interactions between ATP synthase and the mitochondrial membrane environment represent an important frontier in understanding MT-ATP6 function and pathology:

• Membrane curvature: ATP synthase oligomers play a critical role in shaping the inner mitochondrial membrane, particularly at the cristae tips. Mutations in MT-ATP6 might disrupt these interactions, potentially affecting mitochondrial ultrastructure .

• Lipid environment effects: The lipid composition of the membrane can significantly influence ATP synthase function. Research suggests that considering interactions with the lipid environment is essential for a holistic understanding of ATP synthase function .

• Proton movement pathways: The MT-ATP6 protein forms part of the proton channel, and its interaction with membrane lipids may affect proton translocation efficiency. The specific arrangement of subunit a relative to the c-ring and surrounding lipids creates the pathway for proton movement that drives ATP synthesis .

• Membrane potential maintenance: Proper functioning of MT-ATP6 is crucial for maintaining the mitochondrial membrane potential. Mutations can disrupt this function, leading to membrane depolarization and mitochondrial dysfunction .

A holistic framework for studying ATP synthase requires consideration of these membrane interactions, as they may contribute to the pathophysiology of MT-ATP6-related disorders and could represent potential therapeutic targets .

What therapeutic approaches are being explored for MT-ATP6-related disorders?

While there are currently no approved targeted therapies for MT-ATP6-related disorders, several promising approaches are under investigation:

• Genetic approaches:

  • Mitochondrial replacement therapy to prevent transmission of pathogenic mutations

  • Gene editing technologies adapted for mitochondrial DNA, though these face significant technical challenges due to the unique characteristics of mtDNA

• Metabolic bypass strategies:

  • Supplementation with substrates that can enhance alternative ATP production pathways

  • Compounds that improve mitochondrial bioenergetics downstream of ATP synthase dysfunction

• Mitochondrial biogenesis induction:

  • Approaches to increase mitochondrial mass and function

  • Targeting of "Transcriptional activation of mitochondrial biogenesis" pathways

• Antioxidant therapies:

  • Compounds targeting increased ROS generation observed in MT-ATP6 mutations

  • Mitochondrially-targeted antioxidants that concentrate at the site of ROS production

• Model systems for therapeutic development:

  • Yeast models have proven valuable for understanding the molecular consequences of MT-ATP6 mutations

  • These systems can potentially be leveraged for high-throughput screening of compounds that mitigate the effects of specific mutations

The heterogeneous nature of MT-ATP6 mutations and their variable tissue distribution presents significant challenges for therapeutic development, highlighting the importance of personalized approaches based on specific mutation characteristics and individual patient factors .